These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 33194604)

  • 41. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
    Tevaarwerk AJ; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Trastuzumab Plus Pertuzumab Resistance Does Not Preclude Response to Lapatinib Plus Trastuzumab in HER2-Amplified Colorectal Cancer.
    Fakih MG
    Oncologist; 2018 Apr; 23(4):474-477. PubMed ID: 29330210
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
    Cocco E; Javier Carmona F; Razavi P; Won HH; Cai Y; Rossi V; Chan C; Cownie J; Soong J; Toska E; Shifman SG; Sarotto I; Savas P; Wick MJ; Papadopoulos KP; Moriarty A; Cutler RE; Avogadri-Connors F; Lalani AS; Bryce RP; Chandarlapaty S; Hyman DM; Solit DB; Boni V; Loi S; Baselga J; Berger MF; Montemurro F; Scaltriti M
    Sci Signal; 2018 Oct; 11(551):. PubMed ID: 30301790
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
    Takeda T; Yamamoto H; Kanzaki H; Suzawa K; Yoshioka T; Tomida S; Cui X; Murali R; Namba K; Sato H; Torigoe H; Watanabe M; Shien K; Soh J; Asano H; Tsukuda K; Kitamura Y; Miyoshi S; Sendo T; Toyooka S
    PLoS One; 2017; 12(2):e0171356. PubMed ID: 28158234
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Case of HER2 Mutated Colorectal Cancer Treated Successfully With Fam-Trastuzumab Deruxtecan.
    Reddy A; Nwankwo N; Sekar A; Kumar A
    Cureus; 2023 May; 15(5):e38582. PubMed ID: 37284365
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Case report: Long-term clinical benefit of pyrotinib therapy following trastuzumab resistance in
    Fang X; Mou H; Ying X; Hou X; Wang L; Wu Y; Yan N; Guo L; Liao Q
    Front Oncol; 2022; 12():1024677. PubMed ID: 36620566
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients.
    Larionov AA
    Front Oncol; 2018; 8():89. PubMed ID: 29670855
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
    Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
    Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Response of human epidermal growth factor receptor 2-positive colorectal cancer to lapatinib monotherapy: A case report.
    Guan JL; Liu JH; Wang Q; Cong YW; Chen YX; Huang KF; Huang ML; Huang L
    World J Gastrointest Oncol; 2020 Sep; 12(9):1065-1072. PubMed ID: 33005299
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HER2-targeted therapy: an emerging strategy in advanced colorectal cancer.
    La Salvia A; Lopez-Gomez V; Garcia-Carbonero R
    Expert Opin Investig Drugs; 2019 Jan; 28(1):29-38. PubMed ID: 30513002
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and
    Collins DM; Conlon NT; Kannan S; Verma CS; Eli LD; Lalani AS; Crown J
    Cancers (Basel); 2019 May; 11(6):. PubMed ID: 31141894
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial.
    Li Q; Guan X; Chen S; Yi Z; Lan B; Xing P; Fan Y; Wang J; Luo Y; Yuan P; Cai R; Zhang P; Li Q; Zhong D; Zhang Y; Zou J; Zhu X; Ma F; Xu B
    Clin Cancer Res; 2019 Sep; 25(17):5212-5220. PubMed ID: 31138588
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of Pyrotinib in a Heavily Pretreated Patient with Lung Adenocarcinoma Harboring HER2 Amplification and Exon 20 Insertions: A Case Report.
    Shan J; Ruan J; Tan Y; Yan L; Chen S; Du M; Wang L
    Onco Targets Ther; 2020; 13():9849-9856. PubMed ID: 33061462
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Response to Pyrotinib in a Chinese Patient with Bone-Metastatic Scrotal Paget's Disease Harboring Triple Uncommon HER2 Mutation: A Case Report.
    Guo JJ; Jiao XD; Wu Y; Qin BD; Liu K; Zang YS
    Onco Targets Ther; 2020; 13():6289-6293. PubMed ID: 32753879
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer.
    Fabi A; Merola R; Ferretti G; Di Benedetto A; Antoniani B; Ercolani C; Nisticò C; Papaldo P; Ciccarese M; Sperduti I; Vici P; Marino M; Gori S; Botti C; Malaguti P; Cognetti F; Mottolese M
    Expert Opin Pharmacother; 2013 Apr; 14(6):699-706. PubMed ID: 23472669
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.
    Cameron D; Casey M; Press M; Lindquist D; Pienkowski T; Romieu CG; Chan S; Jagiello-Gruszfeld A; Kaufman B; Crown J; Chan A; Campone M; Viens P; Davidson N; Gorbounova V; Raats JI; Skarlos D; Newstat B; Roychowdhury D; Paoletti P; Oliva C; Rubin S; Stein S; Geyer CE
    Breast Cancer Res Treat; 2008 Dec; 112(3):533-43. PubMed ID: 18188694
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Case Report: Durable Clinical Response to Third-Line Pyrotinib After Resistance to Trastuzumab in a Gastric Cancer Patient.
    Wu J; Li L; Qin J; Yan Z; Chen S; Jin T; Xu J
    Front Oncol; 2021; 11():780577. PubMed ID: 35155188
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity.
    Scaltriti M; Verma C; Guzman M; Jimenez J; Parra JL; Pedersen K; Smith DJ; Landolfi S; Ramon y Cajal S; Arribas J; Baselga J
    Oncogene; 2009 Feb; 28(6):803-14. PubMed ID: 19060928
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow.
    Pohl M; Schmiegel W
    Dig Dis; 2016; 34(5):574-9. PubMed ID: 27332557
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of Afatinib and Lapatinib Against
    Nakata S; Fujita M; Nakanishi H
    Anticancer Res; 2019 Nov; 39(11):5927-5932. PubMed ID: 31704817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.